MovDisordV3, PascalFrancis, Corpus, bibRecord, 002A25

Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

Identifieur interne : 002A25 ( PascalFrancis/Corpus ); précédent : 002A24; suivant : 002A26

Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

Auteurs : Alberto Albanese ; Ubaldo Bonuccelli ; Christine Brefel ; K. Ray Chaudhuri ; Carlo Colosimo ; Tobias Eichhorn ; Eldad Melamed ; Pierre Pollak ; Teus Van Laar ; Mario Zappia

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:01-0333009

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Epreuve pharmacologique, Lévodopa, Antiparkinsonien, Chimiothérapie, Apomorphine, Stimulant dopaminergique, Agoniste, Récepteur dopaminergique, Conférence consensus, Recommandation, Diagnostic, Traitement, Homme.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Chemotherapy, Consensus conference, Diagnosis, Dopamine agonist, Dopamine receptor, Human, Levodopa, Parkinson disease, Pharmacologic test, Recommendation, Treatment.

Abstract

Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease`
A11	`01`	`1`		`@1 ALBANESE (Alberto)`
A11	`02`	`1`		`@1 BONUCCELLI (Ubaldo)`
A11	`03`	`1`		`@1 BREFEL (Christine)`
A11	`04`	`1`		`@1 CHAUDHURI (K. Ray)`
A11	`05`	`1`		`@1 COLOSIMO (Carlo)`
A11	`06`	`1`		`@1 EICHHORN (Tobias)`
A11	`07`	`1`		`@1 MELAMED (Eldad)`
A11	`08`	`1`		`@1 POLLAK (Pierre)`
A11	`09`	`1`		`@1 VAN LAAR (Teus)`
A11	`10`	`1`		`@1 ZAPPIA (Mario)`
A14	`01`			`@1 Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico @2 Milano @3 ITA @Z 1 aut.`
A14	`02`			`@1 Clinica Neurologica, Università di Pisa @2 Pisa @3 ITA @Z 2 aut.`
A14	`03`			`@1 Laboratoire de Pharmacologie Médical et Clinique, INSERM U455 @2 Toulouse @3 FRA @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, King's College Hospital @2 London @3 GBR @Z 4 aut.`
A14	`05`			`@1 Dipartimento di Scienze Neurologiche, Università La Sapienza @2 Roma @3 ITA @Z 5 aut.`
A14	`06`			`@1 Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg @3 DEU @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Beilinson Medical Centre, Sackler Medical School @2 Tel-Aviv @3 ISR @Z 7 aut.`
A14	`08`			`@1 Service de Neurologie, Université J. Fourier @2 Grenoble @3 FRA @Z 8 aut.`
A14	`09`			`@1 Department of Neurology, Leiden University Medical Centre @2 Leiden @3 NLD @Z 9 aut.`
A14	`10`			`@1 Clinica Neurologica, Università di Catanzaro @2 Catanzaro @3 ITA @Z 10 aut.`
A20				`@1 197-201`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000096545190040`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 45 ref.`
A47	`01`	`1`		`@0 01-0333009`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Epreuve pharmacologique @5 04`
C03	`02`	`X`	`ENG`	`@0 Pharmacologic test @5 04`
C03	`02`	`X`	`SPA`	`@0 Prueba farmacológica @5 04`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @5 07`
C03	`03`	`X`	`ENG`	`@0 Levodopa @5 07`
C03	`03`	`X`	`SPA`	`@0 Levodopa @5 07`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 08`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 08`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 08`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 09`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 09`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 09`
C03	`06`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 10`
C03	`07`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 11`
C03	`07`	`X`	`ENG`	`@0 Dopamine agonist @5 11`
C03	`07`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 11`
C03	`08`	`X`	`FRE`	`@0 Agoniste @5 12`
C03	`08`	`X`	`ENG`	`@0 Agonist @5 12`
C03	`08`	`X`	`SPA`	`@0 Agonista @5 12`
C03	`09`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 13`
C03	`09`	`X`	`ENG`	`@0 Dopamine receptor @5 13`
C03	`09`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 13`
C03	`10`	`X`	`FRE`	`@0 Conférence consensus @5 16`
C03	`10`	`X`	`ENG`	`@0 Consensus conference @5 16`
C03	`10`	`X`	`SPA`	`@0 Conferencia consensus @5 16`
C03	`11`	`X`	`FRE`	`@0 Recommandation @5 17`
C03	`11`	`X`	`ENG`	`@0 Recommendation @5 17`
C03	`11`	`X`	`SPA`	`@0 Recomendación @5 17`
C03	`12`	`X`	`FRE`	`@0 Diagnostic @5 18`
C03	`12`	`X`	`ENG`	`@0 Diagnosis @5 18`
C03	`12`	`X`	`SPA`	`@0 Diagnóstico @5 18`
C03	`13`	`X`	`FRE`	`@0 Traitement @5 19`
C03	`13`	`X`	`ENG`	`@0 Treatment @5 19`
C03	`13`	`X`	`SPA`	`@0 Tratamiento @5 19`
C03	`14`	`X`	`FRE`	`@0 Homme @5 20`
C03	`14`	`X`	`ENG`	`@0 Human @5 20`
C03	`14`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 232`

Format Inist (serveur)

NO :	PASCAL 01-0333009 INIST
ET :	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
AU :	ALBANESE (Alberto); BONUCCELLI (Ubaldo); BREFEL (Christine); CHAUDHURI (K. Ray); COLOSIMO (Carlo); EICHHORN (Tobias); MELAMED (Eldad); POLLAK (Pierre); VAN LAAR (Teus); ZAPPIA (Mario)
AF :	Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico/Milano/Italie (1 aut.); Clinica Neurologica, Università di Pisa/Pisa/Italie (2 aut.); Laboratoire de Pharmacologie Médical et Clinique, INSERM U455/Toulouse/France (3 aut.); Department of Neurology, King's College Hospital/London/Royaume-Uni (4 aut.); Dipartimento di Scienze Neurologiche, Università La Sapienza/Roma/Italie (5 aut.); Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg/Allemagne (6 aut.); Department of Neurology, Beilinson Medical Centre, Sackler Medical School/Tel-Aviv/Israël (7 aut.); Service de Neurologie, Université J. Fourier/Grenoble/France (8 aut.); Department of Neurology, Leiden University Medical Centre/Leiden/Pays-Bas (9 aut.); Clinica Neurologica, Università di Catanzaro/Catanzaro/Italie (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 2; Pp. 197-201; Bibl. 45 ref.
LA :	Anglais
EA :	Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.
CC :	002B17G; 002B02B06
FD :	Parkinson maladie; Epreuve pharmacologique; Lévodopa; Antiparkinsonien; Chimiothérapie; Apomorphine; Stimulant dopaminergique; Agoniste; Récepteur dopaminergique; Conférence consensus; Recommandation; Diagnostic; Traitement; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Pharmacologic test; Levodopa; Antiparkinson agent; Chemotherapy; Dopamine agonist; Agonist; Dopamine receptor; Consensus conference; Recommendation; Diagnosis; Treatment; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Prueba farmacológica; Levodopa; Antiparkinsoniano; Quimioterapia; Estimulante dopaminérgico; Agonista; Receptor dopaminérgico; Conferencia consensus; Recomendación; Diagnóstico; Tratamiento; Hombre
LO :	INIST-20953.354000096545190040
ID :	01-0333009

Links to Exploration step

Pascal:01-0333009

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title>
<author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1>
<s2>Milano</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name>
<affiliation><inist:fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name>
<affiliation><inist:fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name>
<affiliation><inist:fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name>
<affiliation><inist:fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1>
<s2>Catanzaro</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0333009</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0333009 INIST</idno>
<idno type="RBID">Pascal:01-0333009</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002A25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title>
<author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1>
<s2>Milano</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name>
<affiliation><inist:fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name>
<affiliation><inist:fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name>
<affiliation><inist:fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name>
<affiliation><inist:fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1>
<s2>Catanzaro</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Consensus conference</term>
<term>Diagnosis</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Pharmacologic test</term>
<term>Recommendation</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Epreuve pharmacologique</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Apomorphine</term>
<term>Stimulant dopaminergique</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Conférence consensus</term>
<term>Recommandation</term>
<term>Diagnostic</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ALBANESE (Alberto)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BONUCCELLI (Ubaldo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BREFEL (Christine)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHAUDHURI (K. Ray)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COLOSIMO (Carlo)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>EICHHORN (Tobias)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MELAMED (Eldad)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>POLLAK (Pierre)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>VAN LAAR (Teus)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ZAPPIA (Mario)</s1>
</fA11>
<fA14 i1="01"><s1>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico</s1>
<s2>Milano</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinica Neurologica, Università di Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, King's College Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Dipartimento di Scienze Neurologiche, Università La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg</s1>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Beilinson Medical Centre, Sackler Medical School</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Service de Neurologie, Université J. Fourier</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Clinica Neurologica, Università di Catanzaro</s1>
<s2>Catanzaro</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>197-201</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000096545190040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>45 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0333009</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Epreuve pharmacologique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Pharmacologic test</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Prueba farmacológica</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Agonist</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Agonista</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Conférence consensus</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Consensus conference</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Conferencia consensus</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>232</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0333009 INIST</NO>
<ET>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</ET>
<AU>ALBANESE (Alberto); BONUCCELLI (Ubaldo); BREFEL (Christine); CHAUDHURI (K. Ray); COLOSIMO (Carlo); EICHHORN (Tobias); MELAMED (Eldad); POLLAK (Pierre); VAN LAAR (Teus); ZAPPIA (Mario)</AU>
<AF>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico/Milano/Italie (1 aut.); Clinica Neurologica, Università di Pisa/Pisa/Italie (2 aut.); Laboratoire de Pharmacologie Médical et Clinique, INSERM U455/Toulouse/France (3 aut.); Department of Neurology, King's College Hospital/London/Royaume-Uni (4 aut.); Dipartimento di Scienze Neurologiche, Università La Sapienza/Roma/Italie (5 aut.); Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps-Universität Marburg/Allemagne (6 aut.); Department of Neurology, Beilinson Medical Centre, Sackler Medical School/Tel-Aviv/Israël (7 aut.); Service de Neurologie, Université J. Fourier/Grenoble/France (8 aut.); Department of Neurology, Leiden University Medical Centre/Leiden/Pays-Bas (9 aut.); Clinica Neurologica, Università di Catanzaro/Catanzaro/Italie (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 2; Pp. 197-201; Bibl. 45 ref.</SO>
<LA>Anglais</LA>
<EA>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</EA>
<CC>002B17G; 002B02B06</CC>
<FD>Parkinson maladie; Epreuve pharmacologique; Lévodopa; Antiparkinsonien; Chimiothérapie; Apomorphine; Stimulant dopaminergique; Agoniste; Récepteur dopaminergique; Conférence consensus; Recommandation; Diagnostic; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Pharmacologic test; Levodopa; Antiparkinson agent; Chemotherapy; Dopamine agonist; Agonist; Dopamine receptor; Consensus conference; Recommendation; Diagnosis; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Prueba farmacológica; Levodopa; Antiparkinsoniano; Quimioterapia; Estimulante dopaminérgico; Agonista; Receptor dopaminérgico; Conferencia consensus; Recomendación; Diagnóstico; Tratamiento; Hombre</SD>
<LO>INIST-20953.354000096545190040</LO>
<ID>01-0333009</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002A25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0333009
   |texte=   Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri